Amyris, a leader in the development and production of sustainable ingredients for the Health & Wellness, Clean Beauty and Flavors & Fragrances markets, sold its Vitamin E royalty agreement to Koninklijke DSM N.V. (Royal DSM). This agreement assigns Amyris’s rights to Vitamin E royalties to DSM in exchange for total consideration of approximately $57 million. In addition, DSM and Amyris have agreed to a further manufacturing cooperation for Amyris products at DSM’s Brotas facility that provides additional capacity and lower cost of goods sold with an expected approximate aggregate benefit of $30–$40 million over the next three years. The expected economic benefit of both agreements to Amyris is approximately $90 million.
Effective 1 April 2019, the joint venture between Royal DSM and Roquette, Reverdia, will be dissolved and the partners will transfer the rights and obligations related to Reverdia’s Biosuccinium® plant in Cassano, Italy to Roquette. Under a non-exclusive license from DSM, Roquette will operate the plant and continue serving customers of Biosuccinium®. Customer service, order processing, and marketing and sales will be integrated into Roquette’s existing business to ensure a smooth transition. DSM, the original developer of the Biosuccinium® technology, will assume the role of exclusive licensor, in line with its business model in this field.
Royal DSM, the Dutch global science-based company in Nutrition, Health and Sustainable Living, is helping professional cyclists 
Amyris, the U.S. industrial bioscience company led by John Melo, closed the second and final tranche of its previously announced financing. The second tranche of $50 million in a private placement was led by a $25 million investment from Koninklijke DSM N.V. (Royal DSM) with the remaining $25 million contributed by Vivo Capital.
